Mechanism of Action of Intrathecal Opioids

Site of Action

The American Society of Clinical Oncology notes that intrathecal opioids exert their analgesic effect by directly binding to mu-opioid receptors in the spinal cord, blocking pain transmission at the spinal level before nociceptive signals ascend to the brain 1
The European Society for Medical Oncology states that intrathecal opioids act primarily on mu-opioid receptors in the substantia gelatinosa of the dorsal horn, where primary afferent neurons synapse with second-order neurons 1
The National Comprehensive Cancer Network guidelines indicate that intrathecal opioids inhibit the release of excitatory neurotransmitters from the presynaptic terminals of nociceptive afferent neurons and hyperpolarize the postsynaptic neurons in the dorsal horn 1

The American College of Clinical Pharmacy recommends that intrathecal administration offers a dramatic advantage in terms of dosing, with oral morphine requiring 300 times the intrathecal dose to achieve equivalent analgesia 1

The National Comprehensive Cancer Network guidelines state that direct administration into the intrathecal space and the smaller required doses result in less brain distribution, potentially avoiding adverse effects such as excessive sedation and confusion 2, 3
The American Society of Clinical Oncology notes that the dramatic reduction in total opioid dose results in fewer systemic side effects, including nausea, vomiting, urinary retention, and respiratory depression, compared to systemic administration 1, 4
The European Society for Medical Oncology states that direct access to spinal receptors provides better pain control than equivalent systemic doses 1, 4

The National Comprehensive Cancer Network guidelines indicate that although the mechanism of action is spinal, clinical efficacy varies depending on pain location, with intrathecal opioids being more likely to be useful for pain localized below the diaphragm 1, 4
The American College of Clinical Pharmacy recommends that intrathecal opioids may be considered for pain in the head, neck, upper and lower limbs, and trunk, although with less predictability 1, 2, 4

The European Society for Medical Oncology (ESMO) guidelines state that intrathecal morphine pumps should be considered only when all of the following criteria are met: inadequate pain relief despite escalating doses of systemic opioids and appropriate adjuvant analgesia, intolerable side effects from systemic opioid therapy, failed opioid rotation or alternative routes of administration, life expectancy > 6 months, and successful trial with temporary epidural or intrathecal catheter demonstrating >50% pain reduction 5, 6, 7
The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommend that intrathecal morphine pumps be reserved for patients with severe, refractory pain who have exhausted conventional options and demonstrated clear benefit during a trial period 5, 8, 9
Contraindications for intrathecal pumps include active infections, coagulopathy or bleeding disorders, and very short life expectancy (<6 months) 6, 7, 9

For cancer pain, conventional oral and parenteral morphine produces effective control in approximately 80% of patients, with only 20% requiring alternative routes of administration 10, 11, 12
About 10% of cancer patients have pain difficult to manage with oral or parenteral drugs, making them potential candidates for interventional techniques 5, 8, 9

The intrathecal route dramatically reduces opioid requirements, with oral morphine requiring 300 times the intrathecal dose for equivalent analgesia, and epidural morphine requiring 24 times the intrathecal dose 6, 8, 9
This translates to only 10% of the systemic dose needed when given intrathecally 5, 13, 14

For patients with truly generalized pain, the algorithm recommends optimizing systemic therapy first, trialing alternative routes if oral route fails, and considering a trial of temporary epidural/intrathecal catheter only if refractory 8, 10, 11, 12
If the trial is successful (>50% pain reduction), proceeding to a permanent implantable pump is recommended, requiring a skilled interdisciplinary team for monitoring and management 6, 7, 5, 13, 14